FDA grants full approval for TIVDAK to treat cervical cancer
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
2024 full-year revenue guidance raised by US$ 2 billion
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Subscribe To Our Newsletter & Stay Updated